Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
- PMID: 18559875
- PMCID: PMC4911537
- DOI: 10.1200/JCO.2007.14.8841
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis
Abstract
Purpose: Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck (SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that are associated with and might predict severe late toxicity after CCRT.
Methods: Patients were analyzed from a subset of three previously reported Radiation Therapy Oncology Group (RTOG) trials of CCRT for locally advanced SCCHN (RTOG 91-11, 97-03, and 99-14). Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube >or= 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years. Case-control analysis was performed, with a multivariable logistic regression model that included pretreatment and treatment potential factors.
Results: A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity. On multivariable analysis, significant variables correlated with the development of severe late toxicity were older age (odds ratio 1.05 per year; P = .001); advanced T stage (odds ratio, 3.07; P = .0036); larynx/hypopharynx primary site (odds ratio, 4.17; P = .0041); and neck dissection after CRT (odds ratio, 2.39; P = .018).
Conclusion: Severe late toxicity after CCRT is common. Older age, advanced T-stage, and larynx/hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was associated with an increased risk of these complications.
Figures


Similar articles
-
Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis.Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):983-9. doi: 10.1016/j.ijrobp.2012.03.005. Int J Radiat Oncol Biol Phys. 2012. PMID: 23078898 Free PMC article. Clinical Trial.
-
Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).Radiother Oncol. 2012 Aug;104(2):213-8. doi: 10.1016/j.radonc.2012.05.004. Epub 2012 Jun 21. Radiother Oncol. 2012. PMID: 22726581 Clinical Trial.
-
Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.J Cancer Res Ther. 2015 Oct-Dec;11(4):723-9. doi: 10.4103/0973-1482.147729. J Cancer Res Ther. 2015. PMID: 26881508 Clinical Trial.
-
Recent advances in combined modality therapy for locally advanced head and neck cancer.Curr Cancer Drug Targets. 2007 Nov;7(7):674-80. doi: 10.2174/156800907782418329. Curr Cancer Drug Targets. 2007. PMID: 18045072 Review.
-
Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.J BUON. 2015 Jul-Aug;20(4):943-53. J BUON. 2015. PMID: 26416042 Review.
Cited by
-
Treatment regimens for laryngeal and hypopharyngeal squamous cell carcinoma: a "real life" multicenter study of 2307 patients.Eur Arch Otorhinolaryngol. 2024 Oct 22. doi: 10.1007/s00405-024-08990-6. Online ahead of print. Eur Arch Otorhinolaryngol. 2024. PMID: 39438293
-
Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.Head Neck. 2014 Jan;36(1):120-5. doi: 10.1002/hed.23275. Epub 2013 Jun 1. Head Neck. 2014. PMID: 23729173 Free PMC article.
-
Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.Oral Oncol. 2020 Jun 16;109:104854. doi: 10.1016/j.oraloncology.2020.104854. Online ahead of print. Oral Oncol. 2020. PMID: 32559724 Free PMC article.
-
Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.Cancer. 2016 Jun 15;122(12):1861-70. doi: 10.1002/cncr.30005. Epub 2016 May 16. Cancer. 2016. PMID: 27182694 Free PMC article.
-
The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population.Curr Oncol. 2013 Aug;20(4):212-9. doi: 10.3747/co.20.1375. Curr Oncol. 2013. PMID: 23904762 Free PMC article.
References
-
- Bourhis J, LeMaitre A, Baujat B, et al: Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 19:188-194, 2007 - PubMed
-
- Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. Lancet 355:949-955, 2000 - PubMed
-
- Brizel DM, Albers MA, Fisher SR, et al: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 328:1798-1804, 1998 - PubMed
-
- Wendt TG, Grabenbauer CG, Rodel CM, et al: Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. J Clin Oncol 16:1318-1324, 1998 - PubMed
-
- Calais G, Alfonsi M, Bardet E, et al: Randomized study comparing radiation alone RT versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086, 1999 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials